Our clinical trials

A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors.

A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non-central Nervous System Tumors That are Amenable to Direct Injection.

First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years

Phase I/II, open-label, multicentre study to evaluate the safety, tolerability, and preliminary efficacy of durvalumab monotherapy or durvalumab in combination with tremelimumab in paediatric patients with advanced solid tumours, haematological malignancies including lymphoma and acute leukaemias

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors.

European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

A Study to Test the Safety of the Investigational Drug Loxo-195 in Children and Adults That May Treat Cancer

Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma

Molecular and Immunological Characterisation of high risk CHildhood Cancer At DiagnOsis, treatment and follow-up - Biological evaluation in children, adolescents and young adults.

Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response)